Do we know the best treatment modality in early stage endometrial cancer?

Bogusław Lindner

,

Jagna Staniaszek

,

Joanna Jońska

,

Mariusz Bidziński

,

Norbert Piotrkowicz

,

Ryszard Krynicki

Endometrial cancer is the most common female malignancy of the menopausal period The basic treatment for endometrial cancer is surgery, in some cases, followed by irradiation tailored to the extend of surgery, depth of myometial invasion, lymph node involvement and the tumor grade Currently, most authors recommend no further treatment in low-risk patients and adjuvant radiotherapy in high-risk patients Because the survival probability at this stage of disease is still about 90%, there is no wide margin to improve the survival That’s why the adjuvant radiotherapy in early stage endometrial cancer, especially in intermediate risk endometrial cancer, is still a matter of controversy Always, when we make a decision about postoperative radiotherapy, we have to balance the probability of local control against the survival benefit of irradiation and late complication rate Future studies are warranted to define, whether any kind of radiotherapy should be employed in intermediate-risk patients and which radiotherapy modality should be used in high-risk node negative patients with stage I disease